Glucocorticoid-induced osteoporosis: pathogenesis and prevention

[Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment].

Glucocorticoids (GC) are diffusely used to treat a wide variety of inflammatory and autoimmune disorders, including rheumatic diseases. GC-induced osteoporosis (GIO) is the most common and serious side-effect for patients receiving GC. Loss of bone mineral density (BMD) is greatest in the first few months of GC use; fracture (Fx) risk is significantly increased at the spine and hip on doses eve...

The pathogenesis of glucocorticoid-induced osteoporosis

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

UNLABELLED Glucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and n...

Calcitonin in the prevention and treatment of glucocorticoid-induced osteoporosis

Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.

OBJECTIVE To summarize the literature concerning the use of bisphosphonates in the prevention and treatment of corticosteroid-induced osteoporosis and make recommendations concerning the proper use of these agents. SEARCH STRATEGIES We conducted a literature search to identify studies in the English language concerning the use of bisphosphonates in the prevention or treatment of corticosteroi...